Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer

European Journal of Cancer Care

Volumn 27, Issue 1, 2018, Pages

  Zemplenyi A T ^a   Kalo Z ^b   Kovacs G ^c   Farkas, R ^d   Beothe T ^d   Banyai D ^d   Sebestyen Z ^d   Endrei, D ^a   Boncz, I ^a   Mangel, L ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c Syreon Research Institute   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

cost effectiveness analysis; hypofractionation; prostate cancer; radiotherapy

Indexed keywords

AGED; COMPARATIVE STUDY; CONFORMAL RADIOTHERAPY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE PLANNING; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; MARKOV CHAIN; PROCEDURES; PROSTATE TUMOR; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MARKOV CHAINS; PROSTATIC NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RISK FACTORS;

EID: 84957999147     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12430     Document Type: Article

References (51)

1. Abramowitz M.C., Li T., Buyyounouski M.K., Ross E., Uzzo R.G., Pollack A. & Horwitz E.M. (2008) The phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer 112, 55–60.
2. American Cancer Society (2012) Cancer facts & figures 2012. American Cancer Society. Available at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012.
3. Arcangeli G., Saracino B., Gomellini S., Petrongari M.G., Arcangeli S., Sentinelli S., Marzi S., Landoni V., Fowler J. & Strigari L. (2010) A Prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer. International Journal of Radi-ation Oncology Biology Physics 78, 11–18.
4. Bauman G., Rumble R.B., Chen J., Loblaw A. & Warde P. (2012) Intensity-modulated radiotherapy in the treatment of prostate cancer. Clinical Oncology (Royal College of Radiologists Great Britain) 24, 461–473 Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-84864762535&partnerID=tZOtx3y1.
5. Boncz I., Nagy J., Sebestyén A. & Kőrösi L. (2004) Financing of health care services in Hungary. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care 5, 252–258. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15714346.
6. Botrel T.E.A., Clark O., Pompeo A.C.L., Bretas F.F.H., Sadi M.V., Ferreira U. & Dos Reis R.B. (2013) Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radi-ation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis. Core Evidence 8, 1–13. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3596128&tool=pmcentrez&rendertype=abstract.
7. Briggs A., Sculpher M. & Claxton K. (2006) Decision modelling for health economic evaluation. [online] Available at: http://books.google.com/books?hl=hu&lr=&id=NuYRBAAAQBAJ&pgis=1.
8. Dasu A. & Toma-Dasu I. (2012) Prostate alpha/beta revisited – an analysis of clinical results from 14 168 patients. Acta Oncologica 51, 963–974.
9. Dearnaley D.P., Sydes M.R., Graham J.D., Aird E.G., Bottomley D., Cowan R.A., Huddart R.A., Jose C.C., Matthews J.H., Millar J., Moore A.R., Morgan R.C., Russell J.M., Scrase C.D., Stephens R.J., Syndikus I. & Parmar M.K. (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. The Lancet Oncology 8, 475–487.
10. Dearnaley D., Syndikus I., Sumo G., Bidmead M., Bloomfield D., Clark C., Gao A., Hassan S., Horwich A., Huddart R., Khoo V., Kirkbride P., Mayles H., Mayles P., Naismith O., Parker C., Patterson H., Russell M., Scrase C., South C., Staffurth J. & Hall E. (2012) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. The Lancet Oncology 13, 43–54.
11. Dolezel M., Odrazka K., Vaculikova M., Vanasek J., Sefrova J., Paluska P., Zouhar M., Jansa J., Macingova Z., Jarosova L., Brodak M., Moravek P. & Hartmann I. (2010) Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost. Strahlen-therapie und Onkologie 186, 197–202. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20354663.
12. Endrei D., Zemplényi A., Molics B., Agoston I. & Boncz I. (2014) The effect of performance-volume limit on the DRG based acute care hospital financing in Hungary. Health Policy (Amsterdam, Netherlands) 115, 152–156. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24406058.
13. Hoffman K.E., Voong K.R., Pugh T.J., Skinner H., Levy L.B., Takiar V., Choi S., Du W., Frank S.J., Johnson J., Kanke J., Kudchadker R.J., Lee A.K., Mahmood U., McGuire S.E. & Kuban D.A. (2014) Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial. International Journal of Radiation Oncology Biology Physics 88, 1074–1084. Available at: http://dx.doi.org/10.1016/j.ijrobp.2014.01.015.
14. Howden L. & Meyer J. (2011) Age and sex composition: 2010. US Census Bureau (May), pp. 1–15. Available at: http://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf.
15. Hummel S.R., Simpson E.L., Hemingway P., Stevenson M.D. & Rees A. (2010) Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment (Winchester, England) 14, 1–108, iii–iv. Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-78149330629&partnerID=tZOtx3y1.
16. Hummel S.R., Stevenson M.D., Simpson E.L. & Staffurth J.N. (2012) A model of the cost-effectiveness of intensity-modulated radiotherapy in comparison with three-dimensional conformal radiotherapy for the treatment of localised prostate cancer. Clinical Oncology 24, e159–e167. Available at: http://dx.doi.org/10.1016/j.clon.2012.09.003.
17. Hungarian Central Statistical Office (2013) Demographics – Census 2011. Census 2011. Budapest. Available at: http://www.ksh.hu/nepszamlalas/tablak_demografia.
18. Hungarian Ministry of Health (2007) Prostate Cancer Treatment Protocol, pp. 1–32. Available at: http://webcache.googleusercontent.com/search?q=cache:7F7ujfIUI-kJ:www.eum.hu/download.php?docID=2907+&cd=1&hl=hu&ct=clnk&gl=de.
19. International Agency for Research on Cancer (2012) Estimated incidence, mortality & prevalence, 2012, EUCAN Cancer Factsheets. Available at: http://eco.iarc.fr/eucan/CancerOne.aspx?Cancer=29&Gender=1.
20. Kaló Z., Bodrogi J., Boncz I., Dózsa C., Jóna G., Kövi R., Pásztélyi Z. & Sinkovits B. (2013) Capacity building for HTA implementation in middle-income countries: the case of Hungary. Value in Health Regional Issues 2, 264–266. Available at: http://dx.doi.org/10.1016/j.vhri.2013.06.002.
21. Kirichenko A.V., Ruth K., Horwitz E.M., Buyyounouski M.K., Feigenberg S.J., Chen D.Y., Pollack A. & Lack A. (2006) Intensity modulated radiation therapy for prostate cancer: preliminary results on treat- ment morbidity compared to 3-D conformal radiation therapy. International Journal of Radiation Oncology Biology Physics 66, 326.
22. Konski A., Watkins-Bruner D., Feigenberg S., Hanlon A., Kulkarni S., Beck J.R., Horwitz E.M. & Pollack A. (2006) Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer. International Journal of Radiation Oncology Biology Physics 66, 408–415.
23. Koontz B.F., Bossi A., Cozzarini C., Wiegel T., D'Amico A. & D'Amico A. (2015) A systematic review of hypofractionation for primary management of prostate cancer. European Urology 68, 683–691. Available at: http://linkinghub.elsevier.com/retrieve/pii/S0302283814007519.
24. Krahn M., Bremner K.E., Tomlinson G., Ritvo P., Irvine J. & Naglie G. (2007) Responsiveness of disease-specific and generic utility instruments in prostate cancer patients. Quality of Life Research 16, 509–522. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17091359.
25. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S. & Pollack A. (2011) Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? International Journal of Radiation Oncology Biology Physics 79, 1310–1317.
26. Kuban D.A., Nogueras-Gonzalez G.M., Hamblin L., Lee A.K., Choi S., Frank S.J., Nguyen Q.N., Hoffman K.E., McGuire S.E. & Munsell M.F. (2010) Preliminary report of a randomized dose escalation trial for prostate cancer using hypofractionation. International Journal of Radiation Oncology Biology Physics 78, S58–S59. Available at: http://dx.doi.org/10.1016/j.ijrobp.2010.07.170.
27. Lennernäs B., Nilsson S. & Levitt S. (2011) Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio – possible reasons for concerns? An example of five dimensional radiotherapy. Acta Oncologica 50(Suppl. 1), 111–115. Available at: http://www.tandfonline.com/doi/full/10.3109/0284186X.2011.562536.
28. Ministry of Human Capacities (2013) Hungarian guidelines for economic evaluation of health care technologies. Egészségügyi Közlöny 11, 1314–1334.
29. Miralbell R., Roberts S.A., Zubizarreta E. & Hendry J.H. (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets:?a/ß = 1.4 (0.9-2.2) Gy. International Journal of Radiation Oncology Biology Physics 82, 17–24.
30. Moraes F.Y., Siqueira G.M., Abreu C.E., da Silva J.L. & Gadia R. (2014) Hypofractioned radiotherapy in prostate cancer: is it the next step? Expert Review of Anticancer Therapy 14, 1271–1276. Available at: http://www.tandfonline.com/doi/abs/10.1586/14737140.2014.972380?journalCode=iery20.
31. National Institute for Health and Care Excellence (2014) Prostate cancer: diagnosis and treatment, NICE clinical guideline 175. NICE clinical guideline 175. Available at: https://www.nice.org.uk/guidance/cg175/resources/guidance-prostate-cancer-diagnosis-and-treatment-pdf.
32. Ohri N., Dicker A.P. & Showalter T.N. (2012) Late toxicity rates following definitive radiotherapy for prostate cancer. The Canadian Journal of Urology 19, 6373–6380. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808959/.
33. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., Van Putten W.L.J., Slot A., Dielwart M.F.H., Bonfrer J.M.G., Incrocci L. & Lebesque J.V. (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. Journal of Clinical Oncology 24, 1990–1996.
34. Pollack A., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Konski A.A., Movsas B., Greenberg R.E., Uzzo R.G., Ma C.M.C., McNeeley S.W., Buyyounouski M.K. & Price R.A. (2006) Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. International Journal of Radiation Oncology Biology Physics 64, 518–526.
35. Pollack A., Walker G., Horwitz E.M., Price R., Feigenberg S., Konski A.A., Stoyanova R., Movsas B., Greenberg R.E., Uzzo R.G., Ma C. & Buyyounouski M.K. (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. Journal of Clinical Oncology 31, 3860–3868.
36. Pollack A., Zagars G.K., Starkschall G., Antolak J.A, Lee J.J., Huang E., von Eschenbach A.C., Kuban D.A & Rosen I. (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology Biology Physics 53, 1097–1105.
37. Ritter M. (2008) Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Seminars in Radiation Oncology 18, 249–256. Available at: http://www.sciencedirect.com/science/article/pii/S1053429608000362.
38. Spyropoulou D. & Kardamakis D. (2012) Review of hypofractionated radiotherapy for prostate cancer. ISRN Oncology 2012, 410892. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3425812&tool=pmcentrez&rendertype=abstract.
39. Stewart S.T., Lenert L., Bhatnagar V. & Kaplan R.M. (2005) Utilities for prostate cancer health states in men aged 60 and older. Medical Care 43, 347–355. Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-17144412624&partnerID=tZOtx3y1.
40. Sullivan P.W., Mulani P.M., Fishman M. & Sleep D. (2007) Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Quality of Life Research 16, 571–575.
41. Tree A.C., Khoo V.S., van As N.J. & Partridge M. (2014) Is biochemical relapse-free survival after profoundly hypofractionated radiotherapy consistent with current radiobiological models? Clin-ical Oncology 26, 216–229. Available at: http://dx.doi.org/10.1016/j.clon.2014.01.008.
42. Viani G.A., Stefano E.J. & Afonso S.L. (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. International Journal of Radiation Oncology Biology Physics 74, 1405–1418.
43. Volk R.J., Cantor S.B., Cass A.R., Spann S.J., Weller S.C. & Krahn M.D. (2004) Preferences of husbands and wives for outcomes of prostate cancer screening and treatment. Journal of General Internal Medicine 19, 339–348. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1492196&tool=pmcentrez&rendertype=abstract.
44. Vora S.A., Wong W.W., Schild S.E., Ezzell G.A. & Halyard M.Y. (2007) Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 68, 1053–1058.
45. Wilt T.J., MacDonald R., Rutks I., Shamliyan T.A., Taylor B.C. & Kane R.L. (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Annals of Internal Medicine 148, 435–448. Available at: http://annals.org/article.aspx?articleID=740046&atab=7.
46. Yamazaki H., Nakamura S., Suzuki G., Yoshida K., Yoshioka Y., Koizumi M. & Ogawa K. (2015) Hypofractionated radiotherapy for localized prostate cancer: a challenging accelerated hypofraction-ated radiotherapy. Anticancer Research 35, 5167–5177. Available at: http://ar.iiarjournals.org/content/35/10/5167.long.
47. Yong J.H.E., Beca J., McGowan T., Bremner K.E., Warde P. & Hoch J.S. (2012) Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer. Clinical Oncology 24, 521–531. Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-84864772355&partnerID=tZOtx3y1.
48. Zaorsky N.G., Ohri N., Showalter T.N., Dicker A.P. & Den R.B. (2013) Systematic review of hypofractionated radiation therapy for prostate cancer. Cancer Treatment Reviews 39, 726–736. Available at: http://dx.doi.org/10.1016/j.ctrv.2013.01.008.
49. Zelefsky M.J., Levin E.J., Hunt M., Yamada Y., Shippy A.M., Jackson A. & Amols H.I. (2008) Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. International Journal of Radiation Oncology Biology Physics 70, 1124–1129.
50. Zelefsky M.J., Pei X., Chou J.F., Schechter M., Kollmeier M., Cox B., Yamada Y., Fidaleo A., Sperling D., Happersett L. & Zhang Z. (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. European Urology 60, 1133–1139. Available at: http://www.scopus.com/inward/record.url?eid=2-s2.0-80255136257&partnerID=tZOtx3y1.
51. Zietman A.L., Bae K., Slater J.D., Shipley W.U., Efstathiou J.A., Coen J.J., Bush D.A., Lunt M., Spiegel D. Y., Skowronski R., Rodney Jabola B. & Rossi C.J. (2010) Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. Journal of Clinical Oncology 28, 1106–1111.